Texas Oncology

Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO

Retrieved on: 
金曜日, 5月 31, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Patient, TC, Toxicity, Texas Oncology, Diagnosis, Triple-negative breast cancer, Breast cancer, Gene expression, FLEX, HR, MD, Neoplasm, Taxane, ASCO, Cyclophosphamide, Woman, Breast Cancer Research, Society, Baylor University Medical Center, Quality of life, Medical imaging

Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.

Key Points: 
  • Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.
  • The FLEX study investigates the 3-year outcome of patients with HR+HER2-, genomically High Risk Luminal B-Type early breast cancer, who have undergone treatment consisting of chemotherapy with taxane and cyclophosphamide (TC) or chemotherapy with anthracycline + TC (AC-T).
  • "The ability to tailor treatment regimens to a patient’s tumor biology is crucial to optimize outcomes and quality of life.
  • MammaPrint's utility in guiding treatment planning is highlighted by these new data evaluating chemotherapy selection," said Dr. O'Shaughnessy.

Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care

Retrieved on: 
金曜日, 5月 24, 2024
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Patient, Biology, Transcriptome, Texas Oncology, Blueprint, Breast cancer, MD, ASCO, Abstract, Society, Medical imaging

The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey.

Key Points: 
  • The presented data underscores Agendia’s commitment to advancing individualized management of breast cancer and to providing support throughout a patient’s treatment journey.
  • These studies add to the already robust library of clinical studies demonstrating Agendia’s MammaPrint and BluePrint effectiveness in providing reliable guidance for therapeutic considerations in early-stage breast cancer.
  • Both presentations utilize whole transcriptome data from the prospective, observational real-word evidence FLEX Study ( NCT03053193 ).
  • The following are details of the abstracts that have been accepted at the ASCO 2024 Annual Meeting:
    Presenter: Joyce O'Shaughnessy, MD | Baylor-Sammons Cancer Center, Texas Oncology
    Other Investigator Initiated Abstracts Utilizing MammaPrint + BluePrint:

CURE Media Group and Oncology Nursing News® announce Meaghan Mooney, B.S.N., RN, OCN, as the winner of the 2024 Extraordinary Healer® Award

Retrieved on: 
木曜日, 4月 25, 2024
Congress, Ochsner Health System, Cancer, LPC, OCN, Dana–Farber Cancer Institute, Walter, Washington Convention Center, Pediatrics, Johnson & Johnson, Gayle, CURE, Media Group, Content, Research, Texas Oncology, Survivor, Corporate development, CCLS, Senior, Nursing, Patient, RN, Caregiver, Wonders & Worries, Multimedia, Health, M.A, PEP, Wonders, Breast cancer

Kristen Dahlgren, co-founder of the Pink Eraser Project (PEP) and award-winning journalist, served as the event’s keynote speaker.

Key Points: 
  • Kristen Dahlgren, co-founder of the Pink Eraser Project (PEP) and award-winning journalist, served as the event’s keynote speaker.
  • Photo credit: Rich Kessler
    “We are thrilled to name Meaghan Mooney, B.S.N., RN, OCN, as the winner of the 2024 CURE Extraordinary Healer Award.
  • Initially drawn towards maternity and pediatrics during nursing school, a surgical rotation on an oncology floor led her on a different path.
  • Captivated by the difficult but rewarding nature of the oncology field, Mooney embarked on a fulfilling career dedicated to the care of cancer patients.

CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists

Retrieved on: 
金曜日, 3月 15, 2024
RN, Health, Washington Convention Center, Haematopoietic system, Mentorship, Oncology Nursing Society, Environment, Simmons University, Caregiver, Dana–Farber Cancer Institute, Education, Patient, Research, Transport, Cancer, Wonders, Texas Oncology, Survivor, OSN, Pediatrics, Johnson & Johnson, Media Group, Kidney, Multimedia, Ochsner Health System, Nursing, OCN

This award honors oncology nurses whose compassion and expertise improve the lives of their patients.

Key Points: 
  • This award honors oncology nurses whose compassion and expertise improve the lives of their patients.
  • The award presentations and winner announcement will be held on April 24, 2024 during the Oncology Nursing Society's Annual Congress at The Walter E. Washington Convention Center in Washington, DC.
  • The finalists for the 2024 Extraordinary Healer award are:
    Jessica McDade, B.S.N., RN, OCN.
  • For more information on the 2024 Extraordinary Healer event and to register, please visit the event page .

Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results

Retrieved on: 
金曜日, 1月 12, 2024
Conference call, Texas Oncology, Cancer, Patient, Conference, Research, WAM

FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m.

Key Points: 
  • FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host a conference call with M. Yair Levy, M.D., director of hematologic malignancies research at Texas Oncology and investigator in the CLOVER WaM pivotal study of iopofosine I 131, on Friday, January 19, 2024 at 8:30 a.m.
  • ET.
  • Dr. Levy will join the Cellectar management team to discuss his perspective, as a community-based hemotologist, on the positive topline results of iopofosine I 131 in patients with relapsed/refractory Waldenstrom’s macroglobulinemia, announced on January 8, 2024.
  • Details for the call are as follows:
    Conference call & Webcast Details:

Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition

Retrieved on: 
木曜日, 12月 7, 2023
Health, Science, Research, Clinical Trials, Oncology, HCA Healthcare, Methodist Hospital, Annual general meeting, PST, St. Elizabeth Healthcare (Kentucky), Sickle cell disease, Bone marrow, ASH, BMT, BSN, Malignancy, Exposition, Sarah Cannon Research Institute, SCRI, Abstract, Nursing care plan, Nivolumab, Society, Physician, Monomethyl auristatin E, Safety, McKesson Corporation, Pharmaceutical industry, Nursing, Vaccine, Dacarbazine, MD, Doxorubicin, Texas Oncology, Patient

Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .

Key Points: 
  • Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .
  • Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event.
  • At this year’s ASH Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network , will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.
  • Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.

Carrum Health and Texas Oncology Collaborate on New Breast Cancer Treatment Model

Retrieved on: 
水曜日, 11月 15, 2023
Breast cancer, Immunotherapy, Cancer, Patient, Radiation, SAN, Center of excellence, Toxicity, Carrum, Victoria, Medical imaging, Health insurance, DALLAS, Texas Oncology

SAN FRANCISCO and DALLAS, Nov. 15, 2023 /PRNewswire/ -- Carrum Health, a value-based Centers of Excellence healthcare solution changing how we pay for and deliver cancer and surgical care, and Texas Oncology, one of the largest community-based oncology practices in the U.S., today announced a new collaboration to provide high-quality, cost-effective breast cancer care to patients. Through employers, Carrum Health will offer patients a bundled package for breast cancer care that includes two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology.

Key Points: 
  • Through employers, Carrum Health will offer patients a bundled package for breast cancer care that includes two years of coverage for chemotherapy, radiation, and symptom management from Texas Oncology.
  • "About half of cancer care is delivered in community oncology settings, which makes these providers a critical component in expanding access to high-value cancer care to our members," said Sach Jain, Carrum Health founder and CEO.
  • With the market's only all-inclusive cancer care bundles, Carrum Health offers access to comprehensive breast cancer treatment and follow-up care including all cancer-related costs, such as chemotherapy and immunotherapy, which are high-cost drivers.
  • In addition, Carrum Health and Texas Oncology plan to expand this collaboration to include other cancers, ensuring more Texans are able to benefit from high-value cancer care.

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
土曜日, 10月 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Retrieved on: 
木曜日, 10月 12, 2023
Priority review, Texas Oncology, UCSF, Fred Hutchinson Cancer Research Center, Disease, FDA, Science in newly industrialized countries, Accelerated approval (FDA), NDA, Overlook Medical Center, Journal, Northwell Health, FTD, Fast Track, NYU, American Journal of Clinical Oncology, Roswell Park, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical device, Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).

Key Points: 
  • BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma.
  • MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process.
  • "The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO of MimiVax.

Susan G. Komen® To Host MORE THAN PINK Walk in Austin This Fall

Retrieved on: 
火曜日, 10月 3, 2023
Walkers, THAN, Dell Technologies, Texas Oncology, Patient, Susan, Breast cancer, Disease, Medical imaging, Central Texas

AUSTIN, Texas, Oct. 3, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk in Central Texas this fall. The Austin MORE THAN PINK Walk will take place on Sunday, Oct. 29, 2023.

Key Points: 
  • AUSTIN, Texas, Oct. 3, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, today announced it will host a MORE THAN PINK Walk in Central Texas this fall.
  • The Austin MORE THAN PINK Walk will take place on Sunday, Oct. 29, 2023.
  • "We look forward to welcoming walkers to make a difference in our fight against breast cancer," said Monique Stensrud, executive director at Susan G. Komen.
  • This year's Austin MORE THAN PINK Walk is made possible by the following sponsors: Dell Technologies, Texas Oncology, Clinical Pathology Laboratories, H-E-B and Austin Radiological Association, Auctane, Evamor, Natrelle, Walmart and Grove Wine Bar & Kitchen.